<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05068674</url>
  </required_header>
  <id_info>
    <org_study_id>60978</org_study_id>
    <nct_id>NCT05068674</nct_id>
  </id_info>
  <brief_title>Human Embryonic Stem Cell-Derived Cardiomyocyte Therapy for Chronic Ischemic Left Ventricular Dysfunction</brief_title>
  <acronym>HECTOR</acronym>
  <official_title>A Phase I, Randomized Pilot Study of Human Embryonic Stem Cell-Derived Cardiomyocytes (hESC-CMs) in PaTients With ChrOnic Ischemic Left VentRicular Dysfunction Secondary to Myocardial Infarction (HECTOR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Joseph C. Wu</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stanford University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This clinical study will utilize a new cell therapy approach (Human embryonic stem cells&#xD;
      derived cardiomyocytes or hESC-CMs) to improve survival and cardiac function in patients with&#xD;
      chronic left ventricular dysfunction secondary to MI (Myocardial Infarction).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The phase I dose-escalation pilot study is intended as an initial safety assessment to&#xD;
      establish the MTD prior to the phase II randomized, double-blinded, placebo-controlled study.&#xD;
      An estimated eighteen (18) patients in phase I who are scheduled to undergo cardiac&#xD;
      catheterization and have met all inclusion/exclusion criteria will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 2022</start_date>
  <completion_date type="Anticipated">October 2025</completion_date>
  <primary_completion_date type="Anticipated">October 2025</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <intervention_model_description>Phase I will be a standard 3+3 dose-escalation study to evaluate 3 doses of allogeneic hESC-CMs</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The maximum tolerated dose (MTD) among 3 dose levels of allogeneic human embryonic stem cell-derived cardiomyocytes (hESC-CMs)</measure>
    <time_frame>3 Years</time_frame>
    <description>The primary endpoints are safety and feasibility. The feasibility of preparing and delivering the study product, as well as collecting cardiac MRI variables in subjects will be assessed.</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">18</enrollment>
  <condition>Chronic Ischemic Left Ventricular Dysfunction</condition>
  <arm_group>
    <arm_group_label>Cohort 1</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Low dose (50M cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Medium dose (150M cells)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>High dose (300M cells)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Embryonic Stem Cell-Derived Cardiomyocyte 50M cells</intervention_name>
    <description>50 million (M) cells delivered in a dose of 5M cells per injection over 10 injections.</description>
    <arm_group_label>Cohort 1</arm_group_label>
    <other_name>Human ESC-CMs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Embryonic Stem Cell-Derived Cardiomyocyte 150 cells</intervention_name>
    <description>150M cells delivered in a dose of 15M cells per injection over 10 injections</description>
    <arm_group_label>Cohort 2</arm_group_label>
    <other_name>Human ESC-CMs</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Human Embryonic Stem Cell-Derived Cardiomyocyte 300M cells</intervention_name>
    <description>300M cells delivered in a dose of 30M per injection over 10 injections</description>
    <arm_group_label>Cohort 3</arm_group_label>
    <other_name>Human ESC-CMs</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Be ≥ 21 and &lt; 80 years of age.&#xD;
&#xD;
          -  Provide written informed consent.&#xD;
&#xD;
          -  Have a diagnosis of chronic ischemic left ventricular dysfunction secondary to MI as&#xD;
             defined by previous myocardial infarction documented by an imaging study demonstrating&#xD;
             coronary artery disease with corresponding areas of akinesis, dyskinesis, or severe&#xD;
             hypokinesis.&#xD;
&#xD;
          -  Be a candidate for cardiac catheterization within 5 to 10 weeks of screening.&#xD;
&#xD;
          -  Have been treated with appropriate maximal medical therapy for heart failure or&#xD;
             postinfarction left ventricular dysfunction. For beta-blockade, the patient must have&#xD;
             been on a stable dose of a clinically appropriate beta-blocker for 3 months. For&#xD;
             angiotensinconverting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARBs)&#xD;
             or angiotensin receptor neprilysin inhibitors (ARNIs) or have appropriate medical&#xD;
             indication precluding use of one or both of these agents, the patient must have been&#xD;
             on a stable dose of a clinically appropriate agent for 1 month or within no more than&#xD;
             doubling the dose of any of ARB, ACE inhibitors, and ARNIs over the last 3 months.&#xD;
&#xD;
          -  Left ventricular ejection fraction below 40%.&#xD;
&#xD;
          -  Class II/III NYHA symptoms of heart failure within the 6 months prior to baseline&#xD;
             testing.&#xD;
&#xD;
          -  Hospitalization in the past 6 months or NT pro-BNP &gt; 1200 pg/mL, or &gt;1600 pg/mL if&#xD;
             atrial fibrillation was present.&#xD;
&#xD;
          -  Automated implantable cardioverter-defibrillator (AICD) in place.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a baseline glomerular filtration rate &lt; 35 ml/min/1.73 m2&#xD;
&#xD;
          -  Have a known, serious radiographic contrast allergy.&#xD;
&#xD;
          -  Have a prosthetic aortic valve or heart constrictive device.&#xD;
&#xD;
          -  Have a documented presence of aortic stenosis (aortic stenosis graded as 1.5 cm2 or&#xD;
             less).&#xD;
&#xD;
          -  Have a documented presence of moderate to severe aortic insufficiency&#xD;
             (echocardiographic assessment of aortic insufficiency graded as ≥+2).&#xD;
&#xD;
          -  Have evidence of a life-threatening arrhythmia in the absence of a defibrillator&#xD;
             (nonsustained ventricular tachycardia ≥ 20 consecutive beats or complete second- or&#xD;
             third-degree heart block in the absence of a functioning pacemaker) or QTc interval &gt;&#xD;
             550 ms on screening ECG.&#xD;
&#xD;
          -  AICD firing in the past 60 days prior to enrollment.&#xD;
&#xD;
          -  Be eligible for or require coronary artery revascularization.&#xD;
&#xD;
          -  Have a hematologic abnormality as evidenced by hematocrit &lt; 25%, white blood cell &lt;&#xD;
             2,500/µl, or platelet values &lt; 100,000/µl without another explanation.&#xD;
&#xD;
          -  Have liver dysfunction, as evidenced by enzymes (AST and ALT) greater than three times&#xD;
             the ULN.&#xD;
&#xD;
          -  Have a coagulopathy (INR &gt; 1.3) not due to a reversible cause (i.e., Coumadin).&#xD;
             Patients on Coumadin will be withdrawn 5 days before the procedure and confirmed to&#xD;
             have an INR &lt; 1.3. Patients who cannot be withdrawn from Coumadin will be excluded&#xD;
             from enrollment.&#xD;
&#xD;
          -  Have known allergies to penicillin or streptomycin.&#xD;
&#xD;
          -  Be an organ transplant recipient.&#xD;
&#xD;
          -  Have a history of organ or cell transplant rejection.&#xD;
&#xD;
          -  Have a clinical history of malignancy within 5 years (i.e., patients with prior&#xD;
             malignancy must be disease-free for 5 years), except curatively-treated basal cell&#xD;
             carcinoma, squamous cell carcinoma, or cervical carcinoma.&#xD;
&#xD;
          -  Have a non-cardiac condition that limits lifespan to &lt; 1 year.&#xD;
&#xD;
          -  Be on chronic therapy with immunosuppressant medication, such as corticosteroids or&#xD;
             TNFα antagonists.&#xD;
&#xD;
          -  Be serum-positive for HIV, hepatitis BsAg, or viremic hepatitis C.&#xD;
&#xD;
          -  Be currently participating (or participated within the previous 30 days) in an&#xD;
             investigational therapeutic or device trial.&#xD;
&#xD;
          -  Be a female patient who is pregnant, nursing, or have child-bearing potential but is&#xD;
             not using effective birth control.&#xD;
&#xD;
          -  Tested positive for SARS-CoV-2 within the last 30 days&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>September 24, 2021</study_first_submitted>
  <study_first_submitted_qc>September 24, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 6, 2021</study_first_posted>
  <last_update_submitted>September 24, 2021</last_update_submitted>
  <last_update_submitted_qc>September 24, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 6, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Stanford University</investigator_affiliation>
    <investigator_full_name>Joseph C. Wu</investigator_full_name>
    <investigator_title>Professor of Medicine and Radiology.</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ventricular Dysfunction</mesh_term>
    <mesh_term>Ventricular Dysfunction, Left</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

